The new data for Eisai Co., Ltd./Biogen, Inc.’s Alzheimer’s candidate lecanemab appears sufficient to win FDA approval despite its safety signals, but whether the results are sufficient to clear the next critical hurdle – Medicare reimbursement – remains an open question.
In its final Medicare national coverage determination (NCD) limiting reimbursement for Alzheimer’s drugs to patients enrolled in a study, the...







